{
    "clinical_study": {
        "@rank": "63660", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "Period 1: fasted control \u2192 Period 2: fed control"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "Period 1: fed control \u2192 Period 2: fasted control"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, 2-period, 2-sequence crossover study to evaluate the effect of food on\n      the relative bioavailability of BMN 673 during fasting and fed conditions in healthy male\n      subjects."
        }, 
        "brief_title": "Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Human Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, between the ages of 18 and 55.\n\n          -  Non-smoking for at least 1 year before Screening.\n\n          -  Willing and able to provide informed consent.\n\n          -  Have a BMI between 18 to 30kg/m2.\n\n          -  Willing and able to comply all study procedures.\n\n          -  Have adequate organ function\n\n          -  Sexually active patients must be willing to use an acceptable method of\n             contraception.\n\n        Exclusion Criteria:\n\n          -  History of any illness that might confound the results of the study or pose an\n             additional risk in administering study medication to the subject.\n\n          -  Current use of prescription medication or regular treatment with over-the-counter\n             medications.\n\n          -  Consumption of herbal medications or dietary supplements.\n\n          -  Consumption of more that than 3 units of alcoholic beverages per day.\n\n          -  Consumption of more than five 240-mL servings of coffee or other caffeinated\n             beverage.\n\n          -  History of alcohol or drug abuse or addiction within 6 months of study entry.\n\n          -  Participation in a clinical Study involving administration of an investigational drug\n             within 1 month or 5 half lives (whichever is longer).\n\n          -  Donation of any blood or having had a significant loss of blood with 56 days."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776437", 
            "org_study_id": "673-103"
        }, 
        "intervention": {
            "arm_group_label": [
                "Treatment A", 
                "Treatment B"
            ], 
            "description": "500mcg dose of BMN 673, 2 discrete single doses separated by 21 days", 
            "intervention_name": "BMN 673", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Evansville", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "47710"
                }, 
                "name": "Covance Clinical Research Unit Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Food Effect Study of BMN 673 Administered to Healthy Adult Male Volunteers", 
        "overall_official": {
            "affiliation": "BioMarin Pharmaceutical", 
            "last_name": "Andrew Dorr, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The primary outcome of this study is to evaluate the effect of food on the relative bioavailability of BMN 673. The Pharmacokinetic analyses of plasma BMN 673 concentration-time will be measured using non-compartmental methods.", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776437"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Assess the safety and tolerability of BMN 673 during fasting and fed conditions with the following safety assessments: adverse events, physical examination, vital signs, concomitant medications, clinical laboratory tests and ECG.", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "source": "BioMarin Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioMarin Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}